sarcoma
Conditions
Interventions
AOB group:cycle 1: PEG-rhG-CSF 100µg/kg, once
cycle 2: rhG-CSF 5µg/kg/d, daily up to ANC=2×10^9/L
BOA group:cycle 1: rhG-CSF 5µg/kg/d, daily up to ANC=2×10^9/L
cycle 2: PEG-rhG-CSF 100µg/kg, once.
Sponsors
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Eligibility
Sex/Gender
All
Age
18 Years to 64 Years
Inclusion criteria
Inclusion criteria: 1. Histopathology diagnosed with sarcoma, and suitable for doxorubicin + isocyclophosphamide treatment; 2. Accept at least 2 cycles of chemotherapy; 3. Aged 18 to 65 years, expected survival time >6 months; KPS=70; 4. Normal bone marrow hematopoietic function: ANC=1.5×10^9/L, PLT=80×10^9/L, Hb=100g/L, without hemorrhagic tendency; 5. Before the start of the study, all patients have been fully understood the research and the must sign the informed consent.
Exclusion criteria
Exclusion criteria: 1. Obvious abnormalities in electrocardiogram or echocardiography; 2. Accumulation of doxorubicin >240mg/m2 or epirubicin >360mg/m2; 3. Liver function: ALT, TBIL, AST > 2.5 ULN; 4. Renal function: Cr>1.5ULN; 5. Allergy to the research drug or other genetically engineered products; 6. Suffering from mental or neurological disorders, can not cooperate; 7. Undergoing chemotherapy in 6 months before recruitment; 8. The investigator believes that the patient's condition is not suitable for this clinical study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Incidence of grade 4 neutropenia [ Time Frame: 21 day ];The duration of grade 4 neutropenia [ Time Frame: 21 day ]; | — |
Countries
China
Contacts
Public ContactJing Chen
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Outcome results
None listed